2 results
Approved WMOWill not start
Primary:To estimate the treatment effect of emactuzumab on objective response rate (ORR) by 6 months from initiation of therapy in the blinded phase compared to placeboSecondary:the effect of emactuzumab on clinical outcome assessments (COAs) for:o…
Approved WMORecruiting
The main objective will be to investigate whether treatment with nVNS on top of best medical practice in acute ischemic stroke patients results in smaller infarct volumes compared with the infarct volumes of patients not treated with nVNS.